Clinical Trial Update: Cardio Risk of Acute Schizophrenia Olanzapine Duke [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluating cardiac risk with olanzapine in acute schizophrenia/schizoaffective disorder was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizoaffective Disorder
• Schizophrenia

Drugs mentioned

• Zyprexa (olanzapine)

Snippet

Sponsor: Duke University | Conditions: Schizophrenia, Schizoaffective Disorder | Phase 4 | Status: WITHDRAWN